Vericel Corporation (VCEL) Stock

Vericel Corporation, a biopharmaceutical company operating at the commercial stage, is focused on advancing cellular therapies tailored for the sports medicine and severe burn care sectors within the United States. The company specializes in the research, development, manufacture, and distribution of innovative treatments designed to address critical medical needs.

Vericel's flagship products include MACI, an autologous cellularized scaffold product utilized for repairing symptomatic single or multiple full-thickness cartilage defects of the knee. Another prominent offering is Epicel, designated as a permanent skin replacement humanitarian use device. Epicel is specifically intended for treating both adult and pediatric patients suffering from deep-dermal or full-thickness burns, providing essential therapeutic support.

In its preapproval stage, Vericel is progressing with NexoBrid, a biological orphan product aimed at facilitating eschar removal in adults afflicted with deep partial-thickness and/or full-thickness thermal burns. This product is currently in the registration stage, underscoring the company's commitment to expanding its portfolio of advanced therapeutic solutions.

Originally founded as Aastrom Biosciences, Inc. in 1989, Vericel Corporation maintains its headquarters in Cambridge, Massachusetts. With a strong emphasis on innovation and clinical efficacy, the company continues to leverage its expertise and resources to pioneer groundbreaking treatments that enhance patient outcomes and redefine standards of care in regenerative medicine.